Prospective, Randomized Trial of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome
Status:
Unknown status
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
Aim of the randomized, open-label, multicenter ISAR-REACT 5 trial is to assess whether
ticagrelor is superior to prasugrel in patients with acute coronary syndrome and planned
invasive strategy in terms of clinical outcomes.
Phase:
Phase 4
Details
Lead Sponsor:
Deutsches Herzzentrum Muenchen
Collaborator:
Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)